Fate Therapeutics, Inc. (FATE)
FATENASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$1.91
+0.0450 (+2.41%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $235.84m
- P/E
- –
- EPS, last 4 quarters
- $-1.03
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9500 to $3.23
- Average volume
- 1.33m
- Previous close
- $1.87
Analysts
6 coveringHold2 buy, 4 hold, 0 sell
Targets a year out average $5.70, +198.4% from here
Earnings
next estimate $-0.2900Next report
Dec 2025
0.0%
Mar 2026
+10.3%
Jun 2026
+10.7%
Sep 2026
+7.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.74m | $1.37m | $1.30m | $2.08m |
| Gross profit | $1.74m | $1.37m | $1.30m | $2.08m |
| Operating income | -$34.73m | -$34.72m | -$33.00m | -$31.13m |
| Net income | -$32.25m | -$32.37m | -$31.21m | -$30.16m |
Last four quarters: revenue $6.49m, margin -1941.1%, free cash flow -$105.66m
News
8 latest- Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesFintel · 4 days ago
- Fate Therapeutics Taps Jamie Harrell To Guide Commercial Strategy For FT819 And FT839 RTTNews · Oct 12, 2026
- Fate Therapeutics Receives $15M CIRM Grant To Advance FT819 In Lupus Nephritis RTTNews · Sep 25, 2026
- Fate Therapeutics To Present Off-The-Shelf CAR T Portfolio At ACR Convergence 2026 RTTNews · Sep 16, 2026
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.The Motley Fool · Aug 31, 2026
- Fate Therapeutics Advances FT819 Doses First Patient In Lupus Nephritis Trial RTTNews · Aug 14, 2026
- Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue EstimatesZacks · Aug 6, 2026
- Fate Gets FDA IND Clearance For FT839 To Initiate Phase 1/2 Trial In Autoimmune Diseases RTTNews · Jul 10, 2026
The company
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- fatetherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.